This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
My doctor ordered an MRI, which revealed a five-centimeter tumor on the right side, accompanied by lymph-node involvement. I spent the next seven weeks in a state of utter panic, while also trying to maintain a sense of normalcy for my daughter, who was only four at the time, and work full-time leading marketing for a tech startup.
Continuing advancements within this field deliver new hope to doctors and patients, transforming disease outcomes for previously incurable indications. In 2021, Novo Nordisk Pharmatech, a leading pharmaceutical-grade insulin and Quats product supplier announced plans to enter the enzyme market.
This “synchronization” helps biopharmas such as Pfizer maximize marketing and field efforts across their organizations to improve engagement with healthcare professionals (HCPs). However, many biopharmas fail to synchronize engagement and digital touchpoints in a timely manner for 73% of HCPs. But this change can be doable.
However, the biopharma industries realised that traditional vaccine development and manufacturing techniques, which take around five to 10 years for initial development to large-scale distribution, 1 were inadequate to meet the growing demand for COVID-19 vaccines. The future of platform-based vaccine technology and manufacturing.
billion deal, in which Eli Lilly agreed to acquire two of POINT Biopharma Global’s late-stage radioligand therapies for oncological indications. Can you share an update on the clinical trial for your lead candidate? Hoppin served as lead director of Noria as the two organisations were sold to Bayer Healthcare in June of 2021.
Dr Prasanth Reddy, head of oncology at LabCorp, tells us how the company works with cancer care teams, biopharma partners, and patients as an integral part of the patient journey from testing to treatment. Across LabCorp , we innovate through science and technology, with access to approximately 2,500 [doctors] and PhDs and over 700 patients.
There is also a looming, time-sensitive reality that biopharma companies face once their products hit the market: they need to recoup the costs of development as quickly as possible before drug patents expire and generics threaten sales. sales, medical science liaisons, etc.).
The company has long argued that the current need to use multiple meningococcal vaccines to provide coverage has resulted in confusion among consumers and doctors, leading to poor compliance and low sales.
This fuels an enormous need for effective patient communication and education as new therapies move through the biopharma pipeline. Those of us in the biopharma industry know how fraught drug development can be. As the saying goes, they are individually rare but collectively common. Many people, cumulatively, are affected.
Production and value creation can be regionalised and decentralised, which could lead to a more resilient economic structure. During his time at Genentech Stefan has advanced several small molecules and new modalities (antibody‑drug conjugates, oligonucleotides and peptides) into the clinic as lead chemist and technical development leader.
This alignment leads to smarter, more impactful HCP interactions. FiercePharma: The drive to digital in pharma marketing is overwhelming doctors, 2022hys.org/news/2024-06-surveyperception-scientists-credibility.html Veeva Pulse Field Trends Report, 2023 2. Risk Reduction in the Life Sciences industry Report, 2023 3.
Quantitative survey results can often lead to a false sense of security around pre-selected response options, therefore missing critical contextual information that helps someone truly understand the patient’s perspective. This sub-set of office personnel is valuable and often leads to rich insights if marketers can spend the time/money.
Dr. Rachel Webster leads the production of syndicated primary and secondary market research reports and custom analysis of a wide range of oncology indications. She has a particular interest and expertise in immuno-oncology and received her doctorate from the University of Oxford. About the author.
Reading time: 4 minutes A patient support network isn’t made up of just doctors or nurses. Yet, VMS leads the clinical educator market in patient confidence to start and maintain therapy. VMS BioMarketing strives to make real, personal connections that help patients engage in their treatment regimen.
By starting collaborations early, relationships are initiated and involvement in the project happens during inception, leading to ownership and thereby maximising results. She completed post-doctoral training at Johnson & Johnson and the University of California San Diego in pharmacology and bioengineering.
Regardless of the tactics and strategies employed, I would encourage more biopharma professionals to get personally involved in patient engagement programs. Typically, we think of patient partnerships in terms of their external impact—for example, to help educate doctors and payers. A Patient-Centric Month Leads to Results.
Prior to his work in the biopharma industry, Dr Boshoff was founding Director of the University College London (UCL) Cancer Institute. He earned his medical degree from University of Pretoria in South Africa, a doctorate PhD from the Institute of Cancer Research in London.
Our ambition is to build a modern, industry-leading manufacturing network, by bringing together talented people and cutting-edge processes, technologies and data to reliably deliver high quality, affordable and sustainable medicines and vaccines to patients. Brendan O’Callaghan leads an international network of manufacturing sites.
Inadequate health services can have devastating consequences, especially when it comes to non-communicable diseases (NCD) , such as cardiovascular diseases, cancers and diabetes, which is the leading cause of death globally. Dr. Grace Lomax : Yes, happily. We also threaded into it information that they needed to know.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content